Geneva, Aug. 5 -- International Clinical Trials Registry received information related to the study (NCT05526521) titled 'A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants =2 Years to <12 Years of Age With Uncontrolled Chronic Spontaneous Urticaria (CSU) (LIBERTY-CSU CUPIDKids)' on Aug. 31, 2022.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Sanofi
Condition:
Chronic Spontaneous Urticaria
Intervention:
Drug: Dupilumab
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: August 25, 2022
Target Sample Size: 15
Countries of Recruitment:
Unite...